Germany Chronic Cough Therapeutics Market Analysis

Germany Chronic Cough Therapeutics Market Executive Summary

Germany's Chronic Cough Therapeutics Market was valued at $231 Mn in 2022 and is estimated to reach $376 Mn in 2030, exhibiting a CAGR of 6.3% during the forecast period.

Chronic cough refers to a persistent cough lasting more than eight weeks, distinguishing it from acute coughs associated with short-term conditions. Unlike short-term coughs often linked to infections, chronic cough can indicate a more enduring underlying health problem. Respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications commonly cause a chronic cough. Identifying and addressing the root cause through a thorough medical assessment is essential for effective management. Chronic cough significantly impacts the quality of life, often requiring a comprehensive, multidisciplinary approach involving healthcare professionals such as pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists.

Chronic cough is a common condition in clinical practice, defined as lasting for at least 8 weeks. In Germany, the lifetime prevalence of chronic cough is 6.5%, with a 12-month prevalence of 4.9%. The prevalence of diagnosed chronic cough is 2.8%, and the prevalence of individuals currently prescribed medication for chronic cough is 0.6%. The prevalence of chronic cough is higher in individuals aged 50 years and older. Those with chronic cough often have an increased number of comorbidities, predominantly related to the respiratory system (71.0%), followed by digestive tract disorders (34.0%), and sleep disorders (37.6%). These findings highlight the significant impact of chronic cough on individuals' health and underscore the need for comprehensive management strategies.

Nocion Therapeutics has announced the beginning of dosing for those suffering from persistent cough in a Phase 2a clinical trial that uses their ground-breaking in-house compound, NTX-1175. This novel compound was created especially to treat chronic coughs that are unclear or refractory. The principal aim of the study is to assess the safety and effectiveness of NTX-1175 in individuals with persistent cough. This discovery represents a major advancement in the investigation of possible therapy pathways for people with chronic cough, especially those who are having difficulty accessing efficient treatment choices.

Market Dynamics

Market Growth Drivers

Growing Geriatric Population: The increasing elderly population in Germany is a significant market growth driver for chronic cough therapeutics. The percentage of people aged 65 and over is around 21%, and this is projected to reach 30% by 2050. Older individuals often experience a higher prevalence of respiratory conditions, contributing to the demand for effective cough management solutions.

Rising Awareness and Diagnosis: Improved awareness and early diagnosis of chronic cough contribute to market growth. Efforts in educating both healthcare professionals and the general public about the causes and available treatments for chronic cough are likely to lead to increased demand for therapeutics in the German market.

Advancements in Medical Research and Technology: Ongoing advancements in medical research and technology play a crucial role in the development of innovative and more targeted chronic cough therapeutics. The integration of cutting-edge technologies and a deeper understanding of the underlying mechanisms of chronic cough can lead to the creation of more efficacious treatments, fostering market growth.

Market Restraints

Patient Compliance Issues: The efficacy of therapies for chronic coughs depends on patients adhering to their recommended regimens. On the other hand, issues with patient compliance, like resistance to long-term medicine use or negative side effects, may make treatment plans less effective and limit market growth.

Reimbursement Challenges: Issues related to reimbursement policies and coverage for chronic cough therapeutics may pose a restraint. Limited reimbursement options can affect patient access to expensive medications and impact the market dynamics.

Regulatory Hurdles: Complex regulatory processes and stringent approval requirements in Germany can slow down the introduction of new chronic cough therapeutics. Compliance with regulatory standards may be challenging, creating obstacles for pharmaceutical companies entering the market and launching new products.

Healthcare Policies and Regulatory Landscape

In Germany, the oversight of healthcare policies and regulations related to therapeutic drugs is primarily administered by the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institute (PEI). Operating as a federal agency within the Ministry of Health, BfArM is tasked with the evaluation and approval of drugs intended for the German market, ensuring their safety, efficacy, and quality. The PEI, another regulatory authority, specializes in overseeing advanced therapies and vaccines. Germany aligns with the regulations set forth by the European Medicines Agency (EMA), contributing to a cohesive approach across the European Union. The Institute for Quality and Efficiency in Health Care (IQWiG) plays a role in evaluating the effectiveness and cost-effectiveness of pharmaceuticals. The healthcare policies in Germany strive to strike a balance between facilitating access to innovative treatments and containing costs, creating a robust regulatory framework that safeguards public health while encouraging advancements in medical practices.

Competitive Landscape

Key Players

• Boiron
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Pfizer
• Merck
• Johnson & Johnson
• Novartis
• Teva Pharmaceutical Industries
• Pierre Fabre Laboratories